Top Markets
Coin of the day
Graybug Vision, Inc. Graybug Vision, Inc.

Graybug Vision, Inc.

GRAY
Rankning i aktier #35305
Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical... Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.
Aktiekurs
$2.70
Senast synkroniserad: 2023-05-17
Marknadsvärde
$4.13M
Förändring (1 dag)
0.00%
Förändring (1 år)
0.00%
Land
US
Handel Graybug Vision, Inc. (GRAY)

Kategori

EPS för Graybug Vision, Inc. (GRAY)
EPS per 2026 TTM: 0
Enligt Graybug Vision, Inc.s senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) 0. Vid slutet av 2026 hade bolaget ett EPS på 0, lika med EPS från 2026 som var 0.
EPS-historik för Graybug Vision, Inc. från 2026 till 2026
EPS vid slutet av varje år
År EPS Ändra
Inte tillräckligt med data för de angivna datumen.
EPS för liknande företag eller konkurrenter